Entrar/Registro  
HOME SPANISH
 
Medicina Interna de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Medicina Interna de México >Year 2016, Issue 4


Mercado U
Disease activity assessment of rheumatoid arthritis in daily practice using the clinical disease activity index (CDAI)
Med Int Mex 2016; 32 (4)

Language: Español
References: 6
Page: 415-419
PDF: 438.72 Kb.


Full text




ABSTRACT

Background: The clinical disease activity index (CDAI) with 28 joint counts measures the activity of rheumatoid arthritis (RA) without laboratory tests.
Objetive: To evaluate the CDAI in daily practice in RA patients at one year of the symptoms onset.
Material and Method: A prospective study was done with 120 consecutive patients with early RA ≤ 12 months (101 women, 19 men) seen in the rheumatology consult within 1 year of symptoms onset. The CDAI was divided into four categories: high or severe activity ›22, moderate ›10-22, mild ‹10 and remission ≤2.8. Functional disability (HAQ, health assessment questionnaire, 0-3 score) was also evaluated. A combination of methotrexate and sulfasalazine or chloroquine and low-dose prednisone 2.5-5.0 mg/d was administered.
Results: At baseline, 88 (73%) patients had high activity and 32 (27%) had moderate-mild activity. At 6 months 3% had high activity, whereas 96 (80%) were in remission (median 0, range 0-2.6). At 12 months, 110 patients (91%) were in remission and 6 (5%) had mild activity. The median score of HAQ was 1.4 (range 0.5-3.0) and at 12 months was 0 (range 0-1.2) There was a good correlation between HAQ and CDAI.
Conclusion: The CDAI score is a clinical tool that omits laboratory tests. Remission, defined as a CDAI ≤2.8 was achieved so early as 6 months. This study also showed improvement in functional ability.


Key words: early rheumatoid arthritis, clinical disease activity index (CDAI), remission, health assessment questionnaire (HAQ).


REFERENCIAS

  1. Aletha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-R806.

  2. Singh H, Kumar H, Handa R, Talapatra P, et al. Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: An Indian experience. Arthritis 2011

  3. Slama IB, Allali F, Lakhdar T, El Kabbaj S, et al. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. BMC Muskuloskeletal Dis 2015;16:268.

  4. Aletaha D, Neogi T, Silman AJ, Funovits J, et al. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.

  5. Cardiel MH, Abello-Banfi M, Ruiz-Mercado R, Alarcon- Segovia D. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-D1). Clin Exp Rheumatol 1993;11:117-121.

  6. Mercado U. La era dorada del tratamiento de la artritis reumatoide. Editorial. Rev Med Inst Mex Seguro Soc 2014;52:126-127.






>Journals >Medicina Interna de México >Year 2016, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019